FUBIS (Floxuridine-Alendronate) First-in-class bone-targeted chemotherapy
A single agent that combines tumor cell kill and bone preservation — delivering chemotherapy directly to bone metastases while protecting healthy bone.
A severe disease burden that calls for better therapies
Bone is one of the most common places for cancer to spread. Once tumor cells settle in bone, they disrupt its natural balance — causing pain, fractures and a major loss in quality of life.
What patients face
“Bone metastases are a major cause of morbidity.”(2) Select a complication to learn more.
1) Extrapolated from: Hernandez et al., Incidence of bone metastases in patients with solid tumors, BMC Cancer (2018) 18:44. 2) Oncology Reviews 2017; 11:321.
Two proven drugs, joined into one bone-seeking molecule
Bisphosphonates strengthen bone. Chemotherapy destroys cancer cells. Decades of efforts to effectively combine the two failed — FUBIS joins them in a single bone-targeted duplex drug.
👆 Tap a part of the molecule
Multi-billion market in bone metastases
First-in-class bone-targeted duplex drug platform
De-risked components: approved drugs Alendronate + 5-FdU
Validated preclinical proof-of-concept — efficacy and safety
Highly experienced team of leading oncology experts & institutions
At clinical inflection point — ~€10m required to advance to first-in-human
FUBIS in two and a half minutes
Follow the story of a patient with bone metastases — and see how FUBIS finds the tumor in bone, breaks it down, and helps rebuild the bone. Jump to any chapter.
Chapters
Dual mechanism: inhibiting bone resorption and eliminating tumor cells
Explore the four steps by tapping the numbers on the illustration or the cards — or press play to walk through them automatically.
Mechanism
How FUBIS acts- Localized, targeted activity at metastatic sites
- Direct disruption of tumor–bone interaction
- Inhibition of osteoclast-driven bone resorption
Preclinical findings
What we've observed- Reduced metastatic burden in preclinical models
- Increased new bone generated in preclinical models
- Preclinical evidence supporting further clinical evaluation
Potential patient relevance
Subject to clinical validation- Potential to reduce pain and analgesic need
- Potential to support mobility and daily function
- Potential quality-of-life benefits
Why a new approach is needed
FUBIS is an investigational, preclinical-stage compound. Its potential benefits are subject to clinical validation.
Strong efficacy and safety in bone metastases models
A unique combination of targeted efficacy and a favourable preclinical safety profile.
A large, growing market with significant unmet need
Market reality
- ~1.2 million patients in US & EU annually
- >$20bn global market, growing at ~8–10% CAGR
- Up to 70% of advanced breast & prostate cancers develop bone metastases
Current treatment gap
- Focus on bone protection, not tumor elimination
- Limited impact on disease progression
- Ongoing pain, fractures and quality-of-life burden
Why FUBIS matters
- Dual mechanism: tumor cell kill + bone preservation
- Targeted delivery to metastatic bone sites
- Potential for disease-modifying effect, not just symptom control
A compelling opportunity at a clinical inflection point
Select a stage to see what it involves.
financing round to advance FUBIS through combined Phase 1/2 clinical development
Transaction structure
- Limited, preferential secondary share allocation for participating investors
- Fixed pro rata calculation
- Equity share and price negotiated directly with the patent holder
Use of funds
- CTA-enabling development
- Phase 1/2 clinical execution
Target
- Series B financing following combined Phase 1/2 proof of concept
Key value drivers for FUBIS
Tap a level of the pyramid to explore each value driver.
Clinical, scientific and healthcare entrepreneurship expertise
Frequently asked questions
Partner with us to bring FUBIS to patients
We are raising a Series A to take FUBIS through combined Phase 1/2 clinical development. Get in touch to receive the full investment materials.
Email: werlephilip@gmail.com